CoChat

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

Open access
Aguilera, Oscar, Muñoz-Sagastibelza, María, Torrejón, Blanca, Borrero-Palacios, Aurea, del Puerto-Nevado, Laura, Martínez-Useros, Javier, Rodriguez-Remirez, María, Zazo, Sandra, García, Estela, Fraga, Mario, Rojo, Federico, García-Foncillas, Jesús · 2016 · Oncotarget
Cited by 84

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

// Oscar Aguilera 1 , María Muñoz-Sagastibelza 1 , Blanca Torrejón 1 , Aurea Borrero-Palacios 1 , Laura del Puerto-Nevado 1 , Javier Martínez-Useros 1 , María Rodriguez-Remirez 1 , Sandra Zazo 1 , Estela García 2, 3 , Mario Fraga 2, 3 , Federico Rojo 1 , Jesús García-Foncillas 1 1 Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, 28040 Madrid, Spain 2 Translational Oncology Division, Oncohealth Institute, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain 3 Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA-HUCA), Universidad de Oviedo, 33011 Oviedo, Spain Correspondence to: Federico Rojo, email: frojo@fjd.es Jesús García-Foncillas, email: jgfoncillas@idcsalud.es Keywords: colon cancer, Warburg, vitamin C, GLUT-1 Received: March 30, 2016 Accepted: May 29, 2016 Published: June 15, 2016 ABSTRACT KRAS mutation is often present in many hard-to-treat tumors such as colon and pancreatic cancer and it is tightly linked to serious alterations in the normal cell metabolism and clinical resistance to chemotherapy. In 1931, the winner of the Nobel Prize in Medicine, Otto Warburg, stated that cancer was primarily caused by altered metabolism interfering with energy processing in the normal cell. Increased cell glycolytic rates even in the presence of oxygen is fully recognized as a hallmark in cancer and known as the Warburg effect. In the late 1970's, Linus Pauling and Ewan Cameron reported that vitamin C may have positive effects in cancer treatment, although deep mechanistic knowledge about this activity is still scarce. We describe a novel antitumoral mechanism of vitamin C in KRAS mutant colorectal cancer that involves the Warburg metabolic disruption through downregulation of key metabolic checkpoints in KRAS mutant cancer cells and tumors without killing human immortalized colonocytes. Vitamin C induces RAS detachment from the cell membrane inhibiting ERK 1/2 and PKM2 phosphorylation. As a consequence of this activity, strong downregulation of the glucose transporter (GLUT-1) and pyruvate kinase M2 (PKM2)-PTB dependent protein expression are observed causing a major blockage of the Warburg effect and therefore energetic stress. We propose a combination of conventional chemotherapy with metabolic strategies, including vitamin C and/or other molecules targeting pivotal key players involved in the Warburg effect which may constitute a new horizon in anti-cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10087

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 84

Metadata

Authors
Aguilera, O., Muñoz-Sagastibelza, M., Torrejón, B., Borrero-Palacios, A., del Puerto-Nevado, L., Martínez-Useros, J., Rodriguez-Remirez, M., Zazo, S., García, E., Fraga, M., Rojo, F., & García-Foncillas, J.
Venue
Oncotarget
Published
2016-06-15
Volume
7
Issue
30
Pages
47954-47965
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2432078031
Cited by
84
References
14
FWCI
3.15
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.